Abstract
223Ra-dichloride (Xofigo; Bayer) is an α-emitting radioactive agent used to treat symptomatic bone metastases in patients with castration-resistant prostate cancer in the absence of visceral metastases ([ 1 ][1]). It functions as a calcium analog and causes double-strand DNA breaks in tissue,
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
